comprehensive -WSS

comprehensive

author：focus 2025-09-28 01:40:02 - browse：2833

De-Shaine Murray is working at the cutting edge of neurotechnology. As a postdoctoral fellow at Yale, he is developing a device to monitor the brain following traumatic brain injury or stroke.

He is also trying to fight the long legacy of racism in neuroscience. During 2020, when it was difficult to conduct research, he said, “I got the chance and the ability to read more widely and to just look into the legacy of neuroscience.” He found a direct line from racist pseudoscience like phrenology to disparities in neuroscience today, like how the texture of Black people’s hair can sometimes exclude them from clinical trials because electrodes are not designed for them. In 2021, he co-founded Black in Neuro, an organization dedicated to improving Black representation in neuroscience.

On this episode of the “First Opinion Podcast,” I spoke to him about how the past and present racism in neuroscience could be reflected in the future, especially as neurotechnology like brain implants become more common.

“I’m not saying that whatever electrode that you made or created is racist. But when you have someone who … creates a technology but doesn’t think about the wide range of users that are potentially going to use it, then that’s where the problem comes in,” he told me.

We also discussed the way inequities in neuroscience research are visible in stroke wards, how brain implants might jump from helping disabled people to being used for human enhancement, and more.

Our conversation was inspired by his recent First Opinion essay, “Neuroscience has to grapple with a long legacy of racism if it wants to move into the future.” The book I mention at the end is “Lock In” by John Scalzi, a great sci-fi mystery exploring themes of race, socioeconomic status, neurotechnology, and more.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Latigo launches with $135 million for Vertex

entertainment

focus

WSS

Report cites 'urgent' need to recruit more diverse clinical trial participants

Long Covid research funding gets a major boost from NIH

Long Covid research funding gets a major boost from NIH

Congress might make insulin pumps more accessible to the blind

Hundreds died while taking an arthritis drug, but nobody alerted patients

Overprescribed: High cost isn't America's only drug problem

knowledge

comprehensive

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

knowledge

How one medical school became remarkably diverse

Latigo launches with $135 million for Vertex

Jerome Adams on the need for new antivirals for Covid

Too many hospitalized Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

U.K. decision on ALS drug has neurologists, advocates up in arms

How one medical school became remarkably diverse

Congress considering partial increase for doctor pay in Medicare

23andMe had bad news about my health. I wish a person had delivered it

Multiple sclerosis has subtypes with different best treatments: study

focus

Republican states more likely to report Covid vaccine side effects

Young boy dies in trial for Pfizer Duchenne gene therapy

Young boy dies in trial for Pfizer Duchenne gene therapy

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Mass General Brigham physicians react to latest merger step

Why Eli Lilly’s earnings didn’t quite live up to the hype

entertainment

focus

focus

hotspot